Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) | MicrobiomeTrials← Back to trialsNCT03998254
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2019-06-26Est. Completion: 2028-03-31
Enrollment target: 6,000 participants Locations- Lingchuan Center for Disease Control and Prevention ( Site 0002), Guilin, Guangxi, China
- Quanzhou Center for Disease Control and Prevention ( Site 0001), Guilin, Guangxi, China
- Xiangyuan Center for Disease Control and Prevention ( Site 0003), Changzhi, Shanxi, China
- Yanhu Center for Disease Control and Prevention of Yuncheng ( Site 0004), Yuncheng, Shanxi, China
- Mianyang Center for Disease Control and Prevention ( Site 0005), Mianyang, Sichuan, China
- Santai County Center for Disease Control and Prevention ( Site 0006), Mianyang, Sichuan, China
Other microbiome trials you might be interested in
Idiopathic CD4-PositiveT-Lymphocytopenia
Idiopathic CD4 lymphocytopenia (ICL) is a rare syndrome defined by consistently low CD4 T cell counts (\<300/mm\^3) with…
Bethesda, United StatesEst. completion Oct 31, 2030
EBVHSVVZVHPVCMV
Background:
* Infections caused by viruses are common causes of illnesses: the common cold, many ear infections, sore t…
Bethesda, United States
Respiratory Recurrent Papillomatosis (RRP)Human Papillomavirus (HPV)Papillomavirus InfectionLaryngeal DiseasesTracheal DiseasesRespiratory Tract Neoplasm
Background:
Recurrent respiratory papillomatosis (RRP) is a rare disease that causes wart-like growths called papilloma…
Bethesda, United StatesEst. completion Jul 1, 2029